Charles River Laboratories Intl. Inc vs United Airlines Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $303.81 (market cap $14.23B), while United Airlines Holdings Inc trades at $106.89 (market cap $34.87B). The key difference: United Airlines Holdings Inc is far larger — about 2.5× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and United Airlines Holdings Inc for 46 Days on average.
| CRL | UAL | |
|---|---|---|
Market Cap | $14.23B | $34.87B |
Volume | 1,176,885 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $310.77 | $136.11 |
52-Week Low | $149.93 | $85.21 |
Typical Hold Time | 33 Days | 46 Days |
Enterprise Value | $17.06B | $51.90B |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
United Airlines (UAL) trades at $105.65, down 4.1% today, with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with revenue growth from $57.1B in 2024 to $59.1B in 2025 and net income of $3.35B. Valuation metrics appear attractive with P/E of 10.06 and P/S of 0.56. Recent news highlights aggressive customer acquisition strategies targeting Delta and American Airlines' premium travelers with status-match offers and Starlink-enabled WiFi advantages.
The investment outlook remains positive given strong analyst consensus (66% buy rating) with $158.10 price target representing 50% upside. Key risks include rising fuel costs, labor expenses, and competitive pressures. Earnings momentum continues with three consecutive quarterly beats, though Q3 2026 results will be crucial for maintaining investor confidence amid current technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →